- Home
- TBI vs FULC Comparison
TBI vs FULC Comparison
Compare TBI & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBI
- FULC
- Stock Information
- Founded
- TBI 1985
- FULC 2015
- Country
- TBI United States
- FULC United States
- Employees
- TBI N/A
- FULC N/A
- Industry
- TBI Professional Services
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- TBI Consumer Discretionary
- FULC Health Care
- Exchange
- TBI Nasdaq
- FULC Nasdaq
- Market Cap
- TBI 255.1M
- FULC 221.5M
- IPO Year
- TBI 1996
- FULC 2019
- Fundamental
- Price
- TBI $8.53
- FULC $4.34
- Analyst Decision
- TBI Buy
- FULC Hold
- Analyst Count
- TBI 2
- FULC 10
- Target Price
- TBI $11.50
- FULC $7.44
- AVG Volume (30 Days)
- TBI 170.3K
- FULC 872.0K
- Earning Date
- TBI 11-04-2024
- FULC 11-13-2024
- Dividend Yield
- TBI N/A
- FULC N/A
- EPS Growth
- TBI N/A
- FULC N/A
- EPS
- TBI N/A
- FULC N/A
- Revenue
- TBI $1,673,611,000.00
- FULC $80,871,000.00
- Revenue This Year
- TBI N/A
- FULC $2,820.53
- Revenue Next Year
- TBI N/A
- FULC N/A
- P/E Ratio
- TBI N/A
- FULC N/A
- Revenue Growth
- TBI N/A
- FULC 2987.86
- 52 Week Low
- TBI $6.63
- FULC $2.86
- 52 Week High
- TBI $16.14
- FULC $13.70
- Technical
- Relative Strength Index (RSI)
- TBI 59.30
- FULC 63.62
- Support Level
- TBI $8.60
- FULC $3.94
- Resistance Level
- TBI $9.05
- FULC $4.64
- Average True Range (ATR)
- TBI 0.38
- FULC 0.33
- MACD
- TBI 0.07
- FULC 0.08
- Stochastic Oscillator
- TBI 68.18
- FULC 81.90
About TBI TrueBlue Inc.
TrueBlue Inc is a provider of staffing and workforce management solutions. Its reportable segments include PeopleReady offers industrial staffing services. PeopleManagement offers contingent and productivity-based on-site industrial staffing services and PeopleScout offers recruitment process outsourcing, talent advisory services, and managed service provider services. It generates maximum revenue from the PeopleReady segment.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.